IL251619B - Preparations containing synergistic combinations of auristatin - Google Patents

Preparations containing synergistic combinations of auristatin

Info

Publication number
IL251619B
IL251619B IL251619A IL25161917A IL251619B IL 251619 B IL251619 B IL 251619B IL 251619 A IL251619 A IL 251619A IL 25161917 A IL25161917 A IL 25161917A IL 251619 B IL251619 B IL 251619B
Authority
IL
Israel
Prior art keywords
auristatin
synergistic
combinations
synergistic auristatin
auristatin combinations
Prior art date
Application number
IL251619A
Other languages
English (en)
Hebrew (he)
Other versions
IL251619A0 (en
Inventor
Sapra Puja
SHOR Boris
Original Assignee
Pfizer
Sapra Puja
SHOR Boris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer, Sapra Puja, SHOR Boris filed Critical Pfizer
Publication of IL251619A0 publication Critical patent/IL251619A0/en
Publication of IL251619B publication Critical patent/IL251619B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/402—1-aryl substituted, e.g. piretanide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6857—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from lung cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL251619A 2014-10-10 2017-04-06 Preparations containing synergistic combinations of auristatin IL251619B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462062192P 2014-10-10 2014-10-10
PCT/IB2015/057457 WO2016055907A1 (en) 2014-10-10 2015-09-29 Synergistic auristatin combinations

Publications (2)

Publication Number Publication Date
IL251619A0 IL251619A0 (en) 2017-06-29
IL251619B true IL251619B (en) 2020-10-29

Family

ID=54288858

Family Applications (1)

Application Number Title Priority Date Filing Date
IL251619A IL251619B (en) 2014-10-10 2017-04-06 Preparations containing synergistic combinations of auristatin

Country Status (12)

Country Link
US (1) US10617670B2 (cg-RX-API-DMAC7.html)
EP (2) EP3204005A1 (cg-RX-API-DMAC7.html)
JP (1) JP6784668B2 (cg-RX-API-DMAC7.html)
KR (1) KR20170058432A (cg-RX-API-DMAC7.html)
CN (1) CN107106685A (cg-RX-API-DMAC7.html)
AU (1) AU2015329625B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017006113A8 (cg-RX-API-DMAC7.html)
CA (1) CA2907878A1 (cg-RX-API-DMAC7.html)
IL (1) IL251619B (cg-RX-API-DMAC7.html)
MX (1) MX2017004580A (cg-RX-API-DMAC7.html)
RU (1) RU2717570C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016055907A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105377994B (zh) 2013-08-22 2018-03-02 索尼公司 水溶性荧光染料或有色染料及其使用方法
KR20250029292A (ko) 2016-04-01 2025-03-04 소니그룹주식회사 초휘도 이량체성 또는 중합체성 염료
US9851359B2 (en) 2016-04-06 2017-12-26 Sony Corporation Of America Ultra bright dimeric or polymeric dyes with spacing linker groups
KR102526802B1 (ko) 2016-05-11 2023-05-02 소니그룹주식회사 초고명도 이량체성 또는 중합체성 염료
US12018159B2 (en) 2016-07-29 2024-06-25 Sony Group Corporation Ultra bright dimeric or polymeric dyes and methods for preparation of the same
US12145956B2 (en) 2017-10-05 2024-11-19 Sony Group Corporation Programmable polymeric drugs
US12290571B2 (en) 2017-10-05 2025-05-06 Sony Group Corporation Programmable dendritic drugs
WO2019088176A1 (ja) * 2017-10-31 2019-05-09 国立大学法人神戸大学 抗体薬物複合体効果増強剤
WO2019099789A1 (en) 2017-11-16 2019-05-23 Sony Corporation Programmable polymeric drugs
NZ764948A (en) * 2017-11-30 2024-08-30 Ladrx Corp Albumin-binding prodrugs of auristatin e derivatives
WO2019140227A1 (en) 2018-01-12 2019-07-18 Sony Corporation Phosphoalkyl ribose polymers comprising biologically active compounds
US12076407B2 (en) 2018-01-12 2024-09-03 Sony Group Corporation Polymers with rigid spacing groups comprising biologically active compounds
WO2019182765A1 (en) 2018-03-19 2019-09-26 Sony Corporation Use of divalent metals for enhancement of fluorescent signals
JP7515786B2 (ja) 2018-03-21 2024-07-16 ソニーグループ株式会社 リンカー基を有するポリマータンデム色素
WO2020006285A1 (en) 2018-06-27 2020-01-02 Sony Corporation Polymeric dyes with linker groups comprising deoxyribose
KR102718543B1 (ko) 2019-09-26 2024-10-18 소니그룹주식회사 링커 그룹을 갖는 중합체성 탠덤 염료
JP7556194B2 (ja) * 2019-12-13 2024-09-26 Ｔｏｐｐａｎホールディングス株式会社 細胞構造体及びその使用
US20240132725A1 (en) 2020-12-07 2024-04-25 Sony Group Corporation Spacing linker group design for brightness enhancement in dimeric or polymeric dyes

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4846978B2 (ja) 2001-10-30 2011-12-28 メルク セローノ ソシエテ アノニム タンパク質チロシンホスファターゼのオキシンドールヒドラジンモジュレータ
US7196090B2 (en) 2002-07-25 2007-03-27 Warner-Lambert Company Kinase inhibitors
KR101520209B1 (ko) * 2003-11-06 2015-05-13 시애틀 지네틱스, 인크. 리간드에 접합될 수 있는 모노메틸발린 화합물
WO2007030642A2 (en) 2005-09-07 2007-03-15 Medimmune, Inc. Toxin conjugated eph receptor antibodies
CN102929901B (zh) 2006-06-26 2016-12-14 尼尔森（美国）有限公司 提高数据仓库性能的方法和装置
MY146420A (en) 2006-09-15 2012-08-15 Pfizer Prod Inc Pyrido (2, 3-d) pyrimidinone compounds and their use as pi3 inhibitors
CL2008001334A1 (es) * 2007-05-08 2008-09-22 Genentech Inc Anticuerpo anti-muc16 disenado con cisteina; conjugado que lo comprende; metodo de produccion; formulacion farmaceutica que lo comprende; y su uso para tratar el cancer.
US8529895B2 (en) 2007-10-02 2013-09-10 Chugai Seiyaku Kabushiki Kaisha Method for suppressing the development of graft-versus-host-disease by administering interleukin 6 receptor antibodies
EP2294072B1 (en) 2008-05-23 2017-03-29 Wyeth LLC Triazine compounds as p13 kinase and mtor inhibitors
CN119552249A (zh) * 2010-06-08 2025-03-04 基因泰克公司 半胱氨酸改造的抗体和偶联物
TWI545134B (zh) * 2010-10-22 2016-08-11 西雅圖遺傳學公司 以奧裡斯他汀（ＡＵＲＩＳＴＡＴＩＮ）為主之抗體藥物結合物及ＰＩ３Ｋ－ＡＫＴ ｍＴＯＲ路徑抑制劑間的協同功效
KR101529810B1 (ko) 2011-04-01 2015-06-26 와이어쓰 엘엘씨 항체-약물 접합체
SG11201401815XA (en) * 2011-10-28 2014-05-29 Genentech Inc Therapeutic combinations and methods of treating melanoma
EP2780039B9 (en) * 2011-11-17 2018-04-18 Pfizer Inc Cytotoxic peptides and antibody drug conjugates thereof
TW201431880A (zh) * 2012-11-07 2014-08-16 Pfizer 抗切口３（ａｎｔｉ－ｎｏｔｃｈ３）抗體及抗體－藥物共軛體
MX375284B (es) 2014-04-30 2025-03-06 Pfizer Conjugados de anticuerpo-fármaco anti-proteína tirosina quinasa 7 (anti-ptk7).

Also Published As

Publication number Publication date
US10617670B2 (en) 2020-04-14
RU2717570C2 (ru) 2020-03-24
CN107106685A (zh) 2017-08-29
EP3549583A1 (en) 2019-10-09
RU2017112048A3 (cg-RX-API-DMAC7.html) 2019-05-07
JP6784668B2 (ja) 2020-11-11
US20180228769A1 (en) 2018-08-16
RU2017112048A (ru) 2018-11-15
MX2017004580A (es) 2017-06-27
BR112017006113A8 (pt) 2018-04-24
BR112017006113A2 (pt) 2017-12-19
WO2016055907A1 (en) 2016-04-14
KR20170058432A (ko) 2017-05-26
IL251619A0 (en) 2017-06-29
AU2015329625B2 (en) 2018-04-05
CA2907878A1 (en) 2016-04-10
EP3204005A1 (en) 2017-08-16
JP2017530983A (ja) 2017-10-19
AU2015329625A1 (en) 2017-04-13

Similar Documents

Publication Publication Date Title
IL304663A (en) combination
IL251619A0 (en) Preparations containing synergistic combinations of auristatin
IL247073A0 (en) combination
PT3122358T (pt) Combinações de inibidores do fgfr e cmet para o tratamento do cancro
GB201501859D0 (en) Composition
GB201410905D0 (en) Composition
SG11201704735WA (en) Composition
ZA201704464B (en) Composition
GB201403017D0 (en) Composition
PL2905411T3 (pl) Brama
GB201414910D0 (en) Composition
GB201403561D0 (en) Composition
PT3217964T (pt) Composição
GB201414555D0 (en) Composition
GB201410493D0 (en) Composition
GB201519442D0 (en) Composition
ZA201606127B (en) Composition
GB201420628D0 (en) Composition
GB201415483D0 (en) Composition
GB201400765D0 (en) Self - Closing eyeguard
GB201404390D0 (en) Composition
GB201402648D0 (en) Composition
IL250781A0 (en) preparation
GB201503484D0 (en) Composition
GB201502355D0 (en) Composition

Legal Events

Date Code Title Description
FF Patent granted